On this page
BMP1
bone morphogenetic protein 1
BMP1 is located on the short (p) arm of chromosome 8, at band 8p21.3. Arm ratio per GRCh38 - banding schematic.
Explore chromosome 8 in the library →Available at Jeen Health
Clinical tests that include this
Overview
BMP1 encodes a secreted metalloproteinase crucial for processing extracellular matrix components during tissue development and maintenance. The enzyme acts on multiple substrates, including procollagen molecules that must be cleaved to form mature collagen fibres. This processing activity is particularly important in skeletal tissues, where collagen provides structural integrity to bone and cartilage.
Pathogenic variants in BMP1 follow an autosomal recessive inheritance pattern, meaning two altered copies are typically required for clinical manifestations. When enzyme function is significantly reduced or absent, affected individuals may develop conditions affecting bone strength and skeletal architecture. The gene's role in extracellular matrix assembly makes it relevant to several inherited skeletal disorders recognised within NHS clinical pathways.
What the gene does
The BMP1 protein functions as a zinc-dependent metalloproteinase that cleaves specific peptide bonds in precursor proteins found outside cells. Its primary substrates include the C-terminal propeptides of type I, II, and III procollagens, which must be removed for collagen molecules to assemble into functional fibrils. This enzymatic processing is essential for generating the tensile strength that collagen imparts to bone, skin, tendons, and other connective tissues.
Beyond collagen processing, the enzyme also activates lysyl oxidase, another protein required for cross-linking collagen and elastin fibres. Additionally, BMP1 cleaves chordin, a regulatory molecule that modulates bone morphogenetic protein signalling during embryonic development. Through these diverse activities, the protein coordinates multiple aspects of extracellular matrix organisation and skeletal patterning. The enzyme's proteolytic activity requires calcium ions for optimal function and structural stability of its catalytic domains.
Video: Genetics 101
Chromosome location
BMP1 is located on the short arm of chromosome 8 at position 21.3 (8p21.3). The genomic region encompasses approximately 80 kilobases and contains multiple exons that encode the full-length protein. This chromosomal location has been confirmed through physical mapping studies and is well conserved across mammalian species, suggesting evolutionary importance of the gene's position and regulatory context.
Protein structure
The BMP1 protein spans 986 amino acids and exhibits a modular architecture consisting of multiple functional domains. The N-terminal region contains a Peptidase M12A domain (amino acids 121-320) that houses the catalytic machinery responsible for proteolytic activity. This is followed by a series of five CUB domains: CUB 1 (322-434), CUB 2 (435-546), CUB 3 (591-703), CUB 4 (747-859), and CUB 5 (860-976). These CUB domains likely mediate protein-protein interactions and substrate recognition.
Interspersed among the CUB domains are two calcium-binding EGF-like domains: EGF-like 1 (547-588) and EGF-like 2 (704-743). These calcium-binding regions contribute to the protein's structural stability and may influence its catalytic efficiency. A disordered region (amino acids 83-125) precedes the catalytic domain, potentially providing flexibility for substrate engagement. This complex domain organisation enables BMP1 to recognise and process multiple extracellular matrix substrates with specificity.
Key variants
Pathogenic variants in BMP1 are relatively rare but have been identified in individuals with skeletal dysplasias characterised by bone fragility and growth abnormalities. Most disease-causing variants are loss-of-function changes that reduce or eliminate enzyme activity, including nonsense mutations, frameshift deletions, and alterations affecting the catalytic domain. Because BMP1-related conditions follow autosomal recessive inheritance, affected individuals typically carry pathogenic variants on both gene copies, while heterozygous carriers generally remain asymptomatic.
Sample of pathogenic variants
10 pathogenic / likely-pathogenic variants from ClinVar, ranked by review status (expert-panel-reviewed first). This is a sample; recurrent founder variants in a specific population may not appear here - see the full ClinVar listing via the link above.
| Variant (HGVS) | Protein change | Classification | Evidence | Associated condition |
|---|---|---|---|---|
c.2188dup | p.Gln730fs | Pathogenic | ★★☆☆ | Osteogenesis imperfecta type 13 |
c.208C>T | p.Gln70Ter | Pathogenic/Likely pathogenic | ★★☆☆ | not provided |
c.549C>A | p.Cys183Ter | Pathogenic/Likely pathogenic | ★★☆☆ | Osteogenesis imperfecta type 13 |
c.584dup | p.Gln197fs | Pathogenic | ★★☆☆ | Osteogenesis imperfecta type 13 |
c.1838_1872del | p.Pro613fs | Pathogenic | ★☆☆☆ | not provided |
c.1857G>A | p.Trp619Ter | Pathogenic | ★☆☆☆ | not provided |
c.2675G>A | p.Trp892Ter | Pathogenic | ★☆☆☆ | not provided |
c.312dup | p.Gln105fs | Pathogenic | ★☆☆☆ | not provided |
c.743del | p.Asn248fs | Pathogenic | ★☆☆☆ | not provided |
c.835A>G | p.Arg279Gly | Pathogenic | ★☆☆☆ | Osteogenesis imperfecta type 13 |
Evidence stars indicate ClinVar review status. Individual variant interpretation should always be performed by a qualified clinical laboratory - many variants remain classified as Variants of Uncertain Significance (VUS) pending more research.
Associated conditions
Biallelic pathogenic variants in BMP1 have been associated with forms of osteogenesis imperfecta, a group of conditions characterised by increased bone fragility and susceptibility to fractures. Affected individuals may present with skeletal deformities, short stature, and connective tissue manifestations affecting teeth and ligaments. The severity can vary depending on the specific variants involved and the degree of residual enzyme activity.
Additionally, BMP1 variants contribute to the broader spectrum of skeletal dysplasias, where abnormal bone and cartilage development leads to structural anomalies detectable during foetal development or early childhood. The enzyme's role in collagen processing means that loss of function produces phenotypes overlapping with other collagen-related disorders, though the specific clinical features may help distinguish BMP1-related cases.
No disease links recorded for this gene in our reference set.
Inheritance pattern
Conditions caused by pathogenic BMP1 variants typically follow autosomal recessive inheritance.
When both parents are carriers, each child has a 25% chance of being affected, 50% of being a carrier, and 25% of being unaffected.
UK clinical status
BMP1 is recognised within the NHS Genomic Medicine Service for its involvement in clinically actionable conditions. The gene appears on the Osteogenesis imperfecta panel (R102) and the Skeletal dysplasia panel (R104), both with green classification indicating strong evidence for clinical validity. It is also included in the Fetal anomalies panel (R21), reflecting its relevance to prenatal diagnostics when skeletal abnormalities are detected through imaging. These panel inclusions support the use of BMP1 testing in appropriate clinical contexts within the NHS.
Sources: NHS GMS PanelApp · Genomics England PanelApp · NHS National Genomic Test Directory
Frequently asked questions
What does it mean to be a carrier of a BMP1 variant?
Carriers have one pathogenic BMP1 variant and one typical gene copy, which generally provides sufficient enzyme function for normal skeletal development. Carriers do not usually show symptoms but can pass the variant to their children.
How is BMP1 different from other bone morphogenetic proteins?
Despite its name, BMP1 is not a true bone morphogenetic protein but rather a metalloproteinase that processes collagen precursors. True BMPs (such as BMP2 and BMP4) are signalling molecules in a different protein family that regulate bone and tissue formation through receptor-mediated pathways.
Can BMP1-related conditions be detected before birth?
Some skeletal abnormalities associated with BMP1 variants may be visible on detailed foetal ultrasound scans, particularly if bone development is significantly affected. Genetic testing can confirm BMP1 involvement when skeletal dysplasia is suspected prenatally, though not all cases will be detectable through imaging alone.